AAV4 VP3 Antikörper (AA 450-475)
Dieses Anti-AAV4 VP3-Antikörper ist ein Kaninchen Polyklonal-Antikörper zur Detektion von AAV4 VP3 in WB. Geeignet für Adeno-Associated Virus 4 (AAV-4).
Produktnummer ABIN1732611
Kurzübersicht für AAV4 VP3 Antikörper (AA 450-475) (ABIN1732611)
Target
AAV4 VP3
(Adeno-Associated Virus 4, VP3 (AAV4 VP3))
Reaktivität
Adeno-Associated Virus 4 (AAV-4)
Wirt
Kaninchen
Klonalität
Polyklonal
Applikation
Western Blotting (WB)
-
-
Bindungsspezifität
- AA 450-475
-
Spezifität
- Reacts with 81 kDa capsid VP3 protein of Adeno Associated Virus 4
-
Aufreinigung
- Antigen affinity purified
-
Immunogen
- Synthetic peptide within residues 450-475 of 81 kDa capsid VP3 protein of AAV 4.
-
Isotyp
- IgG
-
-
-
Applikationshinweise
-
Working dilution: Optimal dilutions should be determined by the end user.
The following are guidelines only:
WB (1:500-1:1000) -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1.0 mg/mL
-
Buffer
- PBS, Sodium azide 0.02 %
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Antibodies are guaranteed for 6 month from date of receipt.
-
Haltbarkeit
- 6 months
-
-
- AAV4 VP3 (Adeno-Associated Virus 4, VP3 (AAV4 VP3))
-
Andere Bezeichnung
- AAV4 VP3
-
Substanzklasse
- Viral Protein
-
Hintergrund
- Adenoviruses are DNA viruses that cause upper respiratory tract infections, conjunctivitis, and other infections in humans. Adenoviruses were discovered in 1953. About 47 different types have been identified since then, and about half of them are believed to cause human diseases. Infants and children are most commonly affected by adenoviruses. Adenovirus infections can occur throughout the year, but seem to be most common from fall to spring. Adenoviruses are responsible for 3-5 % of acute respiratory infections in children and 2 % of respiratory illnesses in adults.
Target
-
Sie sind hier:
